| Ytd | 2.63% | |
| 1y | 12.75% |
| Open | 127.28 | Prev Close | 126.34 | Low | 125.13 | High | 127.62 | Mkt Cap | 156.40B |
| Vol | 6.19M | Avg Vol | 7.13M | EPS | 7.34 | P/E | 17.16 | Forward P/E | 13.04 |
| Beta | 0.33 | Short Ratio | 3.02 | Inst. Own | 92.16% | Dividend | 3.28 | Div Yield | 2.60 |
| Ex Div Date | 06-15 | Earning | 08-06 | 50-d Avg | 129.64 | 200-d Avg | 129.83 | 1yr Est | 157.57 |
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend i
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05%
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer,
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin
U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) acc
This donation, along with the additional supply being readied, continues the company's long-stan
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda
– Novel Investigational Combination Pairs Merck's Islatravir, a Next-Generation Nucleoside Analo
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (N
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed
Gilead applauds the leadership of the Government of South Africa and the Global Fund for acceleratin
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization
CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company
Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people
– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal As
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-d
– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinic
Maxim Group analyst Michael Okunewitch upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy an
Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t
Gilead intends to use the net proceeds from this offering for general corporate purposes, which may
Nasdaq jumps 1.6% to record highs Friday as semiconductor rally and stronger-than-expected April pay
Truist Securities analyst Gregory Renza reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and r
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform
Guidance and OutlookFor the full year 2026, Gilead now expects:(in millions, except per share amount
GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (i
GILEAD SCIENCES, INC.RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)(unaudited) (i
Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.03 per share which beat the analyst
Gilead Sciences (NASDAQ: GILD) will release Q1 earnings on May 7, with analysts expecting $1.91 EPS
Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declin
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have bee
– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the N
Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight
Tempus AI (TEM) shares up 3.6% on expanded Gilead oncology deal. Explore technical support levels, A
Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision m
KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise
Gilead shares dip after $3.15 billion Tubulis deal adds ADC asset, as multiple acquisitions reshape
https://www.bloomberg.com/news/articles/2026-04-07/gilead-agrees-to-buy-cancer-biotech-tubulis-in-5-